At CRS, a major research focus has been the development and application of folate-based radioligands for targeting folate receptor (FR)-positive tumor types, as well as radioligands for targeting prostate-specific membrane antigen (PSMA)-expressing prostate cancer [9,10,11,12]. The gene discussed is FOLH1; the disease is neoplasm.